Xeris Pharmaceuticals Inc Stock News

Xeris Biopharma Holdings Inc (NASDAQ: XERS) has reaffirmed its preliminary 2021 pro forma sales at a high-end of $76 million - $80 million guidance, approximately 55% growth from 2020. The company

Find out what's moving markets on the last day of the year.

The FDA approved Recorlev for the treatment of endogenous Cushing's syndrome.

The FDA approved Xeris' Recorlev drug for certain adult patients with Cushing's syndrome, sending XERS stock higher. The post XERS Stock Pops on Huge FDA News.

Here are three penny stocks for your NYE watchlist The post Is the Stock Market Open Today? 3 Penny Stocks to Watch on NYE appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto

Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout 2021 amid delays in p

Equities analysts expect Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) to announce earnings per share (EPS) of ($0.22) for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Xeris Pharmaceuticals earnings. The lowest EPS estimate is ($0.32) and the highest is ($0.17). Xeris Pharmaceuticals reported earnings per share of ($0.41) in the same quarter []

Xeris Biopharma Holdings Inc. (NASDAQ:XERS) traded at $2.41 at last check on Tuesday, December 21, made a downward move of -2.43% on its previous days price. Looking at the stock we see that its previous close was $2.47 with the days price range being $2.26 $2.50. In terms of its 52-week price range, XERS What Is The Outlook For Xeris Biopharma Holdings Inc. (NASDAQ: XERS) Like For Short-Term? Read More »

Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) saw a significant drop in short interest in the month of November. As of November 30th, there was short interest totalling 3,040,000 shares, a drop of 30.9% from the November 15th total of 4,400,000 shares. Based on an average trading volume of 1,720,000 shares, the days-to-cover ratio is currently 1.8 days. [] The post Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Short Interest Update appeared first on ETF Daily News .

SVB Leerink reiterated their buy rating on shares of Xeris Pharmaceuticals (NASDAQ:XERS) in a report published on Thursday, PriceTargets.com reports. The brokerage currently has a $6.00 price target on the stock. Separately, HC Wainwright upped their price target on shares of Xeris Pharmaceuticals from $4.00 to $4.25 and gave the stock a buy rating in []

Xeris Pharmaceuticals acquired Strongbridge Biopharma in a stock swap and contingent value rights transaction. The combined company is now called Xeris Biopharma Holdings. Recorlev is ready for approv

SVB Leerink reaffirmed their buy rating on shares of Xeris Pharmaceuticals (NASDAQ:XERS) in a research report released on Thursday, Price Targets.com reports. They currently have a $6.00 target price on the stock. Separately, HC Wainwright increased their price target on shares of Xeris Pharmaceuticals from $4.00 to $4.25 and gave the stock a buy rating []

In the last trading session, 1.12 million shares of the Xeris Biopharma Holdings Inc. (NASDAQ:XERS) were traded, and its beta was 1.61. Most recently the companys share price was $2.22, and it changed around $0.03 or 1.37% from the last close, which brings the market valuation of the company to $271.40M. XERS currently trades at Xeris Biopharma Holdings Inc. (NASDAQ: XERS) Stock Forecast: $8.00 Per Share In 2021 With Positive Signs Read More »

You can buy these penny stocks for under $5 but are they worth the risk? The post 4 Penny Stocks To Buy For Under $5 Before 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | Pe

Investors need to pay close attention to Xeris (XERS) stock based on the movements in the options market lately.